Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
David Avery, University of Washington
ClinicalTrials.gov Identifier:
NCT00524420
First received: August 30, 2007
Last updated: April 13, 2013
Last verified: April 2013
  Purpose

While acute pain after surgery or trauma comes on suddenly and lasts for a limited amount of time, chronic pain persists and can continue for months and even years. Repetitive transcranial magnetic stimulation (rTMS) uses a magnetic field to deliver a current to the brain and can affect brain activity. The purpose of this study is to determine the effectiveness of rTMS treatment in reducing chronic widespread pain in women.


Condition Intervention Phase
Fibromyalgia
Chronic Pain
Depression
Device: rTMS
Device: Sham rTMS
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Transcranial Magnetic Stimulation (TMS) in the Treatment of Chronic Widespread Pain (CWP)

Resource links provided by NLM:


Further study details as provided by University of Washington:

Primary Outcome Measures:
  • Gracely Box Intensity Rating Scale [ Time Frame: Measured weekly ] [ Designated as safety issue: Yes ]
    The BIRS is reliable, valid, and sensitive measure that has been used in a number of studies of analgesics and studies of changes of pain intensity over time and was selected as the primary outcome variable. Each scale is a 20 point scale that has clear anchor points. Patients will be classified as responders if they have a 4 point drop or more on the BIRS. In order to be randomized, subjects were to have had a BIRS score of at least 8. Lower scores indicate less pain and higher scores indicate more pain. This measure was administered once a week at Baseline, at the end of weeks 1, 2, and 3 of TMS treatment, and 1 week post-TMS treatment.


Secondary Outcome Measures:
  • Gracely Box Unpleasantness Scale [ Time Frame: Measured weekly ] [ Designated as safety issue: Yes ]
    The BURS is reliable, valid, and sensitive measure that has been used in a number of studies of analgesics and studies of changes of pain unpleasantness over time. Each scale is a 20 point scale that has clear anchor points. Pain unpleasantness is different from pain intensity in that it assesses the affective and not the somatic aspect of the pain. Lower scores indicate less unpleasantness of pain and higher scores indicate more unpleasantness of pain. This measure was administered at Baseline, after weeks 1, 2, and 3 of TMS treatment, and 1 week post-TMS.

  • Hamilton Depression Rating Scale [ Time Frame: Measured weekly ] [ Designated as safety issue: Yes ]
    The research coordinator administered the Hamilton Depression Rating Scale-17 item to assess the level of depression on a weekly basis at baseline, weeks 1, 2, 3 of TMS treatment and 1 week post-TMS treatment. Higher scores indicate a higher level of depression. Scores range from 0-50 and scores greater than 20 generally indicate moderate depression. Scores between 0-7 are considered normal.

  • Adverse Events [ Time Frame: Measured daily ] [ Designated as safety issue: Yes ]
    Adverse events (AEs) were collected by open report of emergent symptoms or illness during the study. This form is filled out during baseline, daily before each TMS session by the trained physician administering the TMS, and at each follow-up visit.


Enrollment: 19
Study Start Date: February 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active rTMS
Active rTMS involves administration of real rTMS to the patient.
Device: rTMS
10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
Other Name: Neuronetics 2100 CRS rTMS System
Sham Comparator: Sham rTMS
Sham rTMS is a placebo or inactive form of rTMS for study control and comparison purposes.
Device: Sham rTMS
10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
Other Name: Neuronetics 2100 rTMS and James Long Integrated Sham System

Detailed Description:

Chronic widespread pain is characterized by musculoskeletal pain that lasts for at least 3 months, pain above and below the waist, pain on both the right and left sides, and pain in the head, neck, spine, or back. In addition to fatigue, chronic widespread pain is a hallmark feature of fibromyalgia. Significant physical and emotional effects usually accompany chronic widespread pain and fibromyalgia, making the development of effective treatments a priority. rTMS involves a neurophysiologic technique that directs a current into the brain by using a magnetic field to pass the scalp and skull safely and painlessly. Stimuli are applied to the same brain area several times per second during several consecutive seconds. rTMS has been found to be effective for treating certain types of chronic pain. The purpose of this study is to determine the effectiveness of rTMS treatment in reducing bodily pain associated with chronic widespread pain and/or fibromyalgia in women.

Participants in this study will undergo a diagnostic interview, physical and neurological exam, electrocardiogram, magnetic resonance imaging, and blood and urine collection for screening purposes. Eligible participants will then be randomly assigned to receive either rTMS treatment or sham rTMS treatment. One-hour daily treatment sessions will occur over 15 days. After every five treatment sessions, participants will be interviewed about their pain and depression symptoms, and they will fill out questionnaires about pain, depression, fatigue, sleep, and exercise. Participants will also undergo pain threshold and tolerance testing of their right thumb. On a daily basis, participants will rate their level of pain using a 0 to 20 scale. Follow-up evaluations will occur 1, 4, and 12 weeks after treatment and will include a repeat interview and testing. After the follow-up evaluations, any participants who did not respond to the sham treatment will be offered a series of 15 real rTMS treatment sessions.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of chronic widespread pain as defined by the 1990 American College of Rheumatology guidelines: chronic musculoskeletal pain for at least 3 months; pain above and below the waist; pain on both right and left sides; pain at one axial site (e.g., head, neck, spine, or back)
  • Willing to remain on a stable medical regimen during the entire 6-week course of Phase 1 treatment and 8 weeks prior to rTMS treatment
  • Willing to undergo random assignment and able to attend treatment sessions
  • Willing to remain on a stable psychotherapy regimen if currently receiving psychotherapy that has been ongoing for at least 3 months prior to study entry

Exclusion Criteria:

  • Unable to maintain treatment as usual at stable doses for any medical or psychiatric conditions for 8 weeks prior to and during the study
  • Another medical condition associated with significant pain (e.g., diabetic neuropathy, systemic lupus erythematosus, Rheumatoid arthritis, severe degenerative joint disease)
  • Any condition that might increase the risk of seizures from TMS
  • History of a seizure disorder or family history of a seizure disorder
  • Previous use of TMS
  • Involvement in litigation or disability that is related to fibromyalgia, chronic widespread pain, or depression
  • Current use of proconvulsant medications (e.g., bupropion)
  • Metal in the body that would prevent magnetic resonance imaging (MRI) or TMS (e.g., aneurysm clips, pacemakers, neurostimulators)
  • History of head injury associated with loss of consciousness for more than 15 minutes, brain surgery, or lithium toxicity
  • History of bipolar disorder, schizophrenia, obsessive compulsive disorder, panic disorder, or post-traumatic stress disorder
  • Current substance abuse or dependence
  • Active suicidal intent or plan
  • Severe claustrophobia that would prevent MRI
  • Major depression with psychotic features or a current major depressive episode lasting longer than 5 years
  • Pregnant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00524420

Locations
United States, Washington
Harborview Medical Center
Seattle, Washington, United States, 98104
Sponsors and Collaborators
University of Washington
Investigators
Principal Investigator: David H. Avery, MD University of Washington
  More Information

Additional Information:
Publications:
Responsible Party: David Avery, Study Principal Investigator, University of Washington
ClinicalTrials.gov Identifier: NCT00524420     History of Changes
Other Study ID Numbers: 32656-D, R21AR053963, 1R21AR053963-01, 06-2407-D 01
Study First Received: August 30, 2007
Results First Received: February 13, 2013
Last Updated: April 13, 2013
Health Authority: United States: Federal Government

Keywords provided by University of Washington:
Pain
Fatigue
Chronic Fatigue Syndrome
Chronic Fatigue-Fibromyalgia Syndrome
Depression
Major Depressive Disorder

Additional relevant MeSH terms:
Myofascial Pain Syndromes
Depression
Depressive Disorder
Fibromyalgia
Behavioral Symptoms
Mood Disorders
Mental Disorders
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on April 16, 2014